Elaprase, developed by Shire Human Genetic Therapies (HGT), a business unit of Shire focused on genetic diseases, is said to be the first and only enzyme replacement therapy approved for people suffering from Hunter syndrome. With this approval, Elaprase is now cleared for marketing in two countries in Latin America – Brazil and Mexico.
Sylvie Gregoire, president of Shire HGT, said: “Approval of Elaprase in Brazil further demonstrates our commitment to bringing meaningful treatments to patients across Latin America – and the world.”